Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid.
Contact Information
9 Squares Building, Monalisha Township
Near Zanzarda Chowkdi, Junagadh 362001 (Gujrat, India)
Structure
Product Description
| Details | |
|---|---|
| Chemical Name | ETORICOXIB |
| IUPAC Name | 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridine |
| CAS Number | 202409-33-4 |
| Molecular Formula | C18H15CIN2O2S |
| Synonyms | Algix;Etoxib;Etocox;MK 663;Tauxib;Etobrix;Arcoxia;Kingcox;MK 0663;Etropain |
| Application | For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. |